Trials / Completed
CompletedNCT00307866
Identification of Hepatic Lesions
A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 218 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Resovist (BAY86-4884, SH U 555 A) | Single bolus injection, followed by MRI |
Timeline
- Start date
- 2001-04-01
- Completion
- 2003-05-01
- First posted
- 2006-03-28
- Last updated
- 2009-05-18
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00307866. Inclusion in this directory is not an endorsement.